CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors

Participants will receive CAR T-cell therapy via infusion on Day 0 (given as per treatment guidelines). Prior to CAR T-cell Therapy, participants will begin receiving lymphodepleting chemotherapy on Days -5 through -3 (given as per treatment guidelines).

"Glofitamab is given intravenously at a dose of 2.5mg over 4 hours on Cycle 1 Day 8.~Glofitamab is given intravenously at a dose of 10mg over 2 hours on Cycle 1 Day 15.~Glofitamab is given intravenously at a dose of 30mg over 2 hours on Day 1 of Cycles 2-6 (as relevant)."

Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.